3003834-34-9
3003834-34-9
Chemical Structure
PBX-7016
- CAS No.: 3003834-34-9
- Formula:C27H25N3O8
- Molecular Weight:519.50
InChIKey: LKIONTQYHDYZJF-ZHJPETKGSA-N
SMILES: C[C@@H](O)C(N[C@@H]1C2=C3C(CC1)=C4C(OCO4)=CC3=NC5=C2CN6C5=CC7=C(COC([C@]7(O)CC)=O)C6=O)=O
Biological Activity: PBX-7016 is a DNA topoisomerase I inhibitor and DDX5 degrader. PBX-7016 induces DNA damage and downregulates Survivin, Mcl-1, and XIAP. PBX-7016 exerts a bystander killing effect. PBX-7016 can serve as an ADC payload for the synthesis of ADC. PBX-7016 is applicable to research related to head and neck cancer, non-small cell lung cancer, breast cancer, colorectal cancer, and ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PBX-7016 | 99.20% | PBX-7016 is a DNA topoisomerase I inhibitor and DDX5 degrader. PBX-7016 induces DNA damage and downregulates Survivin, Mcl-1, and XIAP. PBX-7016 exerts a bystander killing effect. PBX-7016 can serve as an ADC payload for the synthesis of ADC. PBX-7016 is applicable to research related to head and neck cancer, non-small cell lung cancer, breast cancer, colorectal cancer, and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. 정두영, et al. Antibody-drug conjugate having camptothecin-based drug linked to antibody having low antigen-binding affinity through linker. WO2024049220A1. 2023-08-30
- [2]. Chun Y, et al. Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential. Journal of medicinal chemistry. 2026 Jan 08;69(1):413-438. [Content Brief]
